Cargando…

Erlotinib in salvage treatment of patients with advanced non-small cell lung cancer: results of an expanded access programme in Poland

AIM OF THE STUDY: Erlotinib and gefitinib are reversible EGFR-TKI administered orally. Results of the phase III study JBR.21 proved the clinical efficacy of erlotinib-based regimens as second- or third-line treatment of advanced NSCLC. We analyze efficacy of treatment with erlotinib in patients suff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kowalski, Dariusz M., Krzakowski, Maciej, Ramlau, Rodryg, Jaskiewicz, Piotr, Janowicz-Żebrowska, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2012
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687401/ https://www.ncbi.nlm.nih.gov/pubmed/23788872 http://dx.doi.org/10.5114/wo.2012.28798

Ejemplares similares

Beta Blockers with Statins May Decrease All-Cause Mortality in Patients with Cardiovascular Diseases and Locally Advanced Unresectable Non-Small-Cell Lung Cancer after Chemoradiotherapy
por: Zaborowska-Szmit, Magdalena, et al.
Publicado: (2023)

Performance-Status Deterioration during Sequential Chemo-Radiotherapy as a Predictive Factor in Locally Advanced Non-Small Cell Lung Cancer
por: Olszyna-Serementa, Marta, et al.
Publicado: (2023)

The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients
por: Kucharczyk, Tomasz, et al.
Publicado: (2015)

Anti-angiogenic agents in the treatment of non-small cell lung cancer
por: Szyszka-Barth, Katarzyna, et al.
Publicado: (2014)

Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancer—Daily Practice versus Clinical Trials
por: Knetki-Wróblewska, Magdalena, et al.
Publicado: (2020)

Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients
por: Krawczyk, Paweł, et al.
Publicado: (2014)

A case of adenoid cystic carcinoma of trachea: treatment complications and radiotherapy role
por: Piórek, Aleksandra, et al.
Publicado: (2021)

Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer
por: Zaborowska-Szmit, Magdalena, et al.
Publicado: (2020)

Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients
por: Pluzanski, Adam, et al.
Publicado: (2020)

Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer
por: Krzakowski, M., et al.
Publicado: (2013)

Elderly Patients with Locally Advanced and Unresectable Non-Small-Cell Lung Cancer May Benefit from Sequential Chemoradiotherapy
por: Zaborowska-Szmit, Magdalena, et al.
Publicado: (2021)

Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma
por: Rybarczyk-Kasiuchnicz, Agnieszka, et al.
Publicado: (2021)

Non-Small-Cell Lung Cancer Patients with Coexistence of High PD-L1 Expression and RET Fusion—Which Path Should We Follow? Case Reports and Literature Review
por: Knetki-Wróblewska, Magdalena, et al.
Publicado: (2022)

Non-Small-Cell Lung Cancer: New Rare Targets—New Targeted Therapies—State of The Art and Future Directions
por: Stencel, Katarzyna, et al.
Publicado: (2021)

Actual status of therapeutic vaccination in non-small cell lung cancer
por: Szyszka-Barth, Katarzyna, et al.
Publicado: (2014)

Overall survival of patients with EGFR mutation-positive non-small-cell lung cancer treated with erlotinib, gefitinib or afatinib under drug programmes in Poland – real-world data
por: Brzozowska, Melania, et al.
Publicado: (2019)

Neoadjuvant and Adjuvant Immunotherapy in Non-Small Cell Lung Cancer—Clinical Trials Experience
por: Chmielewska, Izabela, et al.
Publicado: (2021)

Solitary fibrous tumour along with non-small-cell lung cancer and Doege-Potter syndrome
por: Piórek, Aleksandra, et al.
Publicado: (2019)

Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
por: Wong, Matthew K., et al.
Publicado: (2009)

Current views on molecularly targeted therapy for lung cancer – a review of literature from the last five years
por: Rybarczyk-Kasiuchnicz, Agnieszka, et al.
Publicado: (2018)

The rationale for HPV-related oropharyngeal cancer de-escalation treatment strategies
por: Wierzbicka, Małgorzata, et al.
Publicado: (2015)

Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy
por: Hirsh, Vera, et al.
Publicado: (2007)

Do We Need TNM for Tracheal Cancers? Analysis of a Large Retrospective Series of Tracheal Tumors
por: Piórek, Aleksandra, et al.
Publicado: (2022)

Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure
por: Cho, Kyoung Min, et al.
Publicado: (2015)

Treatment Patterns, Testing Practices, and Outcomes in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer in Poland: A Descriptive Analysis of National, Multicenter, Real-World Data from the REFLECT Study
por: Pluzanski, Adam, et al.
Publicado: (2023)

Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice
por: Knetki-Wróblewska, Magdalena, et al.
Publicado: (2023)

The results of external quality assessment programme on urine leukocyte and erythrocyte counting in Poland
por: Ćwiklińska, Agnieszka, et al.
Publicado: (2020)

Efficacy of Immunotherapy in Second-Line Treatment of KRAS-Mutated Patients with Non-Small-Cell Lung Cancer—Data from Daily Practice
por: Knetki-Wróblewska, Magdalena, et al.
Publicado: (2022)

The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study
por: Krawczyk, Paweł, et al.
Publicado: (2014)

Expanded Access Programme: looking for a common definition
por: Iudicello, Antonella, et al.
Publicado: (2016)

Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy
por: Chiarion-Sileni, V, et al.
Publicado: (2014)

Thymic epithelial tumors: Do we know all the prognostic factors?
por: Knetki‐Wróblewska, Magdalena, et al.
Publicado: (2021)

Air protection programmes in Poland in the context of the low emission
por: Adamczyk, Janusz, et al.
Publicado: (2017)

Crizotinib in the treatment of non-small-cell lung carcinoma
por: Płużański, Adam, et al.
Publicado: (2013)

Regional Variability in the Access to Cardiac Rehabilitation in Poland
por: Jankowiak, Maciej, et al.
Publicado: (2020)

Accession of Poland
Publicado: (1990)

Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis: A successful case report and review
por: Dong, Yong, et al.
Publicado: (2021)

Expanded Access Use of Rezafungin for Salvage Therapy of Invasive Candida glabrata Infection: A Case Report
por: Adeel, Alina, et al.
Publicado: (2021)

The epidemiology of hepatocellular cancer in Poland
por: Wasiak, Dariusz, et al.
Publicado: (2018)

DIEP Flap Salvage of Infected Tissue Expanders
por: Tian, William, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1mkifr933h5e7uebte1gelo7fj